We Claim:

1. A method for treating B cell lymphoma, comprising administering to a patient in need thereof a combination therapy comprising an anti-CD19 antibody and an anti-CD20 antibody, wherein said combination therapy provides anti-tumor activity for a longer duration than either said anti-CD19 antibody or said anti-CD20 antibody administered alone on a comparable dosing schedule.

2. The method of claim 1, wherein said B cell lymphoma is selected from acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL).

3. The method of claim 1, wherein the combination therapy provides a synergistic therapeutic effect.

4. The method of claim 1, wherein the anti-CD19 and anti-CD20 antibodies are administered simultaneously.

5. The method of claim 1, wherein the anti-CD19 and anti-CD20 antibodies are administered sequentially.

6. The method of claim 1, wherein the anti-tumor activity is an inhibition of tumor growth.

7. The method of claim 1, wherein the anti-tumor activity is a depletion of malignant B cells.

8. The method of claim 1, wherein the combination therapy confers anti-tumor activity for at least one month longer than either said anti-CD19 antibody or said anti-CD20 antibody administered singly on a comparable dosing schedule.

9. The method of claim 1, wherein the combination therapy confers anti-tumor activity for at least six months longer than either said anti-CD19 antibody or said anti-CD20 antibody administered singly on a comparable dosing schedule.

10. The method of claim 1, wherein the combination therapy confers anti-tumor activity for at least six months.

11. The method of claim 1, wherein tumor volume in the patient increases by less than 10% during a six month period of treatment with the combination therapy.

12. The method of claim 1, wherein the anti-CD19 antibody has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) as measured in vitro.

13. The method of claim 1, wherein the anti-CD19 antibody is afucosylated.

14. The method of claim 1, wherein the anti-CD19 antibody is a human or humanized antibody.

15. The method of claim 1, wherein the anti-CD19 antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:6, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8.

16. The method of claim 1, wherein the anti-CD19 antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 1.

17. The method of claim 1, wherein the anti-CD19 antibody comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 5.

18. The method of claim 1, wherein the anti-CD19 antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 1 and a VL domain comprising the amino acid sequence of SEQ ID NO: 5.

19. The method of claim 1, wherein the anti-CD20 antibody is rituximab.

20. A method for treating a B cell lymphoma, comprising administering to a patient in need thereof a combination therapy comprising an anti-CD19 antibody and an anti-CD20 antibody, wherein a dosage of said combination therapy has greater anti-tumor activity than a dosage of said anti-CD19 antibody that is at least two-fold higher than the dosage of the combination therapy.

21. The method of claim 20, wherein said B cell lymphoma is selected from acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL).

22. The method of claim 20, wherein the combination therapy provides a synergistic therapeutic effect.

23. The method of claim 20, wherein the anti-CD19 and anti-CD20 antibodies are administered simultaneously.

24. The method of claim 20, wherein the anti-CD19 and anti-CD20 antibodies are administered sequentially.

25. The method of claim 20, wherein the anti-tumor activity is an inhibition of tumor growth.

26. The method of claim 20, wherein the anti-tumor activity is a depletion of malignant B cells.

27. The method of claim 20, wherein the anti-CD19 antibody has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) as measured in vitro.

28. The method of claim 20, wherein the anti-CD19 antibody is afucosylated.

29. The method of claim 20, wherein the anti-CD19 antibody is a human or humanized antibody.

30. The method of claim 20, wherein the anti-CD19 antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:6, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8.

31. The method of claim 20, wherein the anti-CD19 antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 1.

32. The method of claim 20, wherein the anti-CD19 antibody comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 5.

33. The method of claim 20, wherein the anti-CD19 antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 1 and a VL domain comprising the amino acid sequence of SEQ ID NO: 5.

34. The method of claim 20, wherein the anti-CD20 antibody is rituximab.



RECTIFIED SHEET (RULE 91) ISA/US

We Claim:

1. Use of an anti-CD19 antibody and an anti-CD20 antibody in the manufacture of a medicament for treating B cell lymphoma, wherein the anti-CD19 antibody and the anti-CD20 antibody are to be used in a combination therapy and wherein the medicament is to be administered to a patient in need thereof, wherein said combination therapy provides anti-tumor activity for a longer duration than either said anti-CD19 antibody or said anti-CD20 antibody administered alone on a comparable dosing schedule.

2. The use of claim 1, wherein said B cell lymphoma is selected from acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL).

3. The use of claim 1, wherein the combination therapy provides a synergistic therapeutic effect.

4. The use of claim 1, wherein the anti-CD19 and anti-CD20 antibodies are to be administered simultaneously.

5. The use of claim 1, wherein the anti-CD19 and anti-CD20 antibodies are to be administered sequentially.

6. The use of claim 1, wherein the anti-tumor activity is an inhibition of tumor growth.

7. The use of claim 1, wherein the anti-tumor activity is a depletion of malignant B cells.

8. The use of claim 1, wherein the combination therapy confers anti-tumor activity for at least one month longer than either said anti-CD19 antibody or said anti-CD20 antibody administered singly on a comparable dosing schedule.

9. The use of claim 1, wherein the combination therapy confers anti-tumor activity for at least six months longer than either said anti-CD19 antibody or said anti-CD20 antibody administered singly on a comparable dosing schedule.

10. The use of claim 1, wherein the combination therapy confers anti-tumor activity for at least six months.

11. The use of claim 1, wherein tumor volume in the patient increases by less than 10% during a six month period of treatment with the combination therapy.

12. The use of claim 1, wherein the anti-CD19 antibody has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) as measured *in vitro*.

13. The use of claim 1, wherein the anti-CD19 antibody is afucosylated.

14. The use of claim 1, wherein the anti-CD19 antibody is a human or humanized antibody.

15. The use of claim 1, wherein the anti-CD19 antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:6, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8.

16. The use of claim 1, wherein the anti-CD19 antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 1.

17. The use of claim 1, wherein the anti-CD19 antibody comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 5.

18. The use of claim 1, wherein the anti-CD19 antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 1 and a VL domain comprising the amino acid sequence of SEQ ID NO: 5.

19. The use of claim 1, wherein the anti-CD20 antibody is rituximab.

20. Use of an anti-CD19 antibody and an anti-CD20 antibody in the manufacture of a medicament for treating B cell lymphoma, wherein the anti-CD19 antibody and the anti-CD20 antibody are to be used in a combination therapy and wherein the medicament is to be administered to a patient in need thereof, wherein a dosage of said combination therapy has greater anti-tumor activity than a dosage of said anti-CD19 antibody that is at least two-fold higher than the dosage of the combination therapy.

21. The use of claim 20, wherein said B cell lymphoma is selected from acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL).

22. The use of claim 20, wherein the combination therapy provides a synergistic therapeutic effect.

23. The use of claim 20, wherein the anti-CD19 and anti-CD20 antibodies are administered simultaneously.

24. The use of claim 20, wherein the anti-CD19 and anti-CD20 antibodies are administered sequentially.

25. The use of claim 20, wherein the anti-tumor activity is an inhibition of tumor growth.

26. The use of claim 20, wherein the anti-tumor activity is a depletion of malignant B cells.

27. The use of claim 20, wherein the anti-CD19 antibody has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) as measured in vitro.

28. The use of claim 20, wherein the anti-CD19 antibody is afucosylated.

29. The use of claim 20, wherein the anti-CD19 antibody is a human or humanized antibody.

30. The use of claim 20, wherein the anti-CD19 antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:6, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 7, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 8.

31. The use of claim 20, wherein the anti-CD19 antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 1.

32. The use of claim 20, wherein the anti-CD19 antibody comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 5.

33. The use of claim 20, wherein the anti-CD19 antibody comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 1 and a VL domain comprising the amino acid sequence of SEQ ID NO: 5.

34. The use of claim 20, wherein the anti-CD20 antibody is rituximab.